NASDAQ : CRDL
Cardiol Therapeutics Inc. — Key statistics
Healthcare · Drug Manufacturers - Specialty & Generic · Canada
Last price 1.17 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 139.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 135.64M |
| Enterprise Value | 117.02M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 116.82M |
| Shares Outstanding | 116.82M |
| Shares Change (YoY) | +28.88% |
| Shares Change (QoQ) | +5.46% |
| Owned by Insiders (%) | 3.03% |
| Owned by Institutions (%) | 13.06% |
| Float | 91.98M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 8.02 |
| P/TBV Ratio | 8.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 5.55 |
| Quick Ratio | 5.01 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -190.18% |
| Return on Assets (ROA) | -90.92% |
| Return on Invested Capital (ROIC) | -124.20% |
| Return on Capital Employed (ROCE) | -148.81% |
| Weighted Average Cost of Capital (WACC) | 8.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.33M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.73 |
| 52-Week Price Change | -2.63% |
| 50-Day Moving Average | 1.62 |
| 200-Day Moving Average | 1.30 |
| Relative Strength Index (RSI) | 29.52 |
| Average Volume (20 Days) | 1,266,804 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 2.84M |
| Short Previous Month | 3.07M |
| Short % of Shares Out | 2.43% |
| Short % of Float | 3.09% |
| Short Ratio (days to cover) | 1.80 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -25.25M |
| Pretax Income | -24.00M |
| Net Income | -24.00M |
| EBITDA | -25.24M |
| EBIT | -25.25M |
| Earnings Per Share (EPS) | -$0.24 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 18.37M |
| Total Debt | 75,345 |
| Net Cash | 18.29M |
| Net Cash Per Share | $0.16 |
| Equity (Book Value) | 16.92M |
| Book Value Per Share | 0.15 |
| Working Capital | 16.87M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -17.22M |
| Capital Expenditures | -40,609 |
| Depreciation & Amortization | 6,584 |
| Net Borrowing | -39,647 |
| Free Cash Flow | -17.26M |
| FCF Per Share | -$0.15 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -28.88% |
| Shareholder Yield | -28.88% |
| Earnings Yield | -21.62% |
| FCF Yield | -12.72% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $8.55 |
| Price Target Difference | 670.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |